Edwards Lifesciences (NYSE:EW) posted its earnings results on Tuesday. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.11, Bloomberg Earnings reports. The company had revenue of $938.00 million for the quarter, compared to analysts’ expectations of $936.69 million. Edwards Lifesciences had a return on equity of 27.78% and a net margin of 18.11%. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business posted $0.94 earnings per share. Edwards Lifesciences updated its Q2 guidance to $1.05-$1.15 EPS and its FY18 guidance to $4.50-$4.70 EPS.
Shares of EW traded down $2.52 during trading hours on Tuesday, reaching $134.67. 2,111,822 shares of the company’s stock traded hands, compared to its average volume of 1,349,342. The firm has a market capitalization of $28,792.15, a price-to-earnings ratio of 35.44, a price-to-earnings-growth ratio of 2.01 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.80. Edwards Lifesciences has a twelve month low of $97.70 and a twelve month high of $143.22.
In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the transaction, the vice president now directly owns 24,908 shares of the company’s stock, valued at $3,169,293.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Larry L. Wood sold 6,300 shares of the firm’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $138.97, for a total value of $875,511.00. The disclosure for this sale can be found here. Insiders have sold 197,236 shares of company stock worth $26,488,281 over the last three months. Corporate insiders own 1.84% of the company’s stock.
A number of equities research analysts have issued reports on the company. Cowen reiterated a “buy” rating and issued a $165.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, March 20th. SunTrust Banks reiterated a “buy” rating and issued a $180.00 target price on shares of Edwards Lifesciences in a research note on Tuesday, April 10th. Zacks Investment Research cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. Barclays raised their target price on Edwards Lifesciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley raised their target price on Edwards Lifesciences from $130.00 to $138.00 and gave the company an “overweight” rating in a research note on Friday, February 2nd. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $145.92.
COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences (EW) Issues Quarterly Earnings Results, Beats Estimates By $0.11 EPS” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/24/edwards-lifesciences-ew-announces-quarterly-earnings-results.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.